These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2572986)

  • 41. Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems.
    Cunha S; Amaral MH; Lobo JM; Silva AC
    Curr Med Chem; 2016; 23(31):3618-3631. PubMed ID: 27554805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positive pressure infusion of therapeutic agents into brain tissues: mathematical and experimental simulations.
    Gillies GT; Smith JH; Humphrey JA; Broaddus WC
    Technol Health Care; 2005; 13(4):235-43. PubMed ID: 16055972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Nanoparticles for brain delivery of drugs or contrast agents. Application to Alzheimer's disease].
    Andrieux K; Couvreur P
    Biol Aujourdhui; 2012; 206(3):185-90. PubMed ID: 23171841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease.
    Zhang C; Chen J; Feng C; Shao X; Liu Q; Zhang Q; Pang Z; Jiang X
    Int J Pharm; 2014 Jan; 461(1-2):192-202. PubMed ID: 24300213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanotherapeutics for Alzheimer's disease (AD): Past, present and future.
    Fazil M; Shadab ; Baboota S; Sahni JK; Ali J
    J Drug Target; 2012 Feb; 20(2):97-113. PubMed ID: 22023651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." The blood-brain barrier: a physical and conceptual challenge.
    Hachinski V; Lee TY
    Alzheimers Dement; 2009 Sep; 5(5):435-6. PubMed ID: 19751924
    [No Abstract]   [Full Text] [Related]  

  • 48. Strategies to advance translational research into brain barriers.
    Neuwelt E; Abbott NJ; Abrey L; Banks WA; Blakley B; Davis T; Engelhardt B; Grammas P; Nedergaard M; Nutt J; Pardridge W; Rosenberg GA; Smith Q; Drewes LR
    Lancet Neurol; 2008 Jan; 7(1):84-96. PubMed ID: 18093565
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct comparisons of CNS directed therapies are needed.
    Gash DM
    Neurobiol Aging; 1989; 10(5):645-6; discussion 648-50. PubMed ID: 2682330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
    Kanazawa T
    Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cellular and molecular neurosurgery: pathways from concept to reality--part II: vector systems and delivery methodologies for gene therapy of the central nervous system.
    Zlokovic BV; Apuzzo ML
    Neurosurgery; 1997 Apr; 40(4):805-12; discussion 812-3. PubMed ID: 9092854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combining CNS transplantation and gene transfer.
    Breakefield XO
    Neurobiol Aging; 1989; 10(5):647-8; discussion 648-50. PubMed ID: 2812248
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
    Boado RJ
    Drug News Perspect; 2008 Nov; 21(9):489-503. PubMed ID: 19180267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles.
    Patel M; Souto EB; Singh KK
    Expert Opin Drug Deliv; 2013 Jul; 10(7):889-905. PubMed ID: 23550609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders.
    Heinzelman P; Schoborg JA; Jewett MC
    Protein Eng Des Sel; 2015 Oct; 28(10):481-9. PubMed ID: 25877663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insights into direct nose to brain delivery: current status and future perspective.
    Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
    Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Self-assembled amphiphilic core-shell nanocarriers in line with the modern strategies for brain delivery.
    Elezaby RS; Gad HA; Metwally AA; Geneidi AS; Awad GA
    J Control Release; 2017 Sep; 261():43-61. PubMed ID: 28648865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nanoparticle-mediated growth factor delivery systems: A new way to treat Alzheimer's disease.
    Lauzon MA; Daviau A; Marcos B; Faucheux N
    J Control Release; 2015 May; 206():187-205. PubMed ID: 25804873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease.
    Dogra A; Narang RS; Narang JK
    Curr Pharm Des; 2020; 26(19):2257-2279. PubMed ID: 32321393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.